```html

Y‑90 Liver Tumor Syndrome: A Complete Patient Guide

Overview

Y‑90 liver tumor syndrome is not a disease in itself; it describes a collection of side‑effects that can occur after a patient receives yttrium‑90 (Y‑90) radioembolization for primary or metastatic liver tumors. Y‑90 radioembolization (also called Selective Internal Radiation Therapy – SIRT) is a minimally invasive procedure in which tiny glass or resin microspheres loaded with the radioactive isotope yttrium‑90 are injected into the hepatic artery. The microspheres lodge in the tumor’s blood supply and deliver a high dose of localized radiation while sparing most healthy liver tissue.

Most patients who undergo Y‑90 radioembolization experience mild, self‑limited symptoms, but a subset develop a post‑procedure syndrome that can include flu‑like symptoms, abdominal pain, jaundice, and laboratory abnormalities. Because the syndrome mimics other liver complications, clinicians use a specific set of criteria to differentiate it from infection, hepatic failure, or tumor progression.

• Who it affects: Adults with primary liver cancer (hepatocellular carcinoma, HCC) or metastatic disease (most commonly colorectal cancer) who receive Y‑90 radioembolization.
• Prevalence: Reported incidence varies from 5–20 % of treated patients, depending on tumor burden, microsphere type, and pre‑existing liver function (Mayo Clinic, 2022; J Vasc Interv Radiol 2021).

Symptoms

The syndrome typically presents within the first 1–4 weeks after the procedure and resolves within 6–8 weeks for most patients. Symptoms can be mild or, rarely, severe enough to require hospitalization.

General (systemic) symptoms

• Fever or low‑grade chills – Often <38 °C (100.4 °F) or less; may be intermittent.
• Fatigue & malaise – General feeling of tiredness that can limit daily activities.
• Weight loss – Usually <5 % of body weight over a month; related to decreased appetite.
• Night sweats – Common when fever spikes.

Abdominal & gastrointestinal symptoms

• Right upper quadrant (RUQ) or epigastric pain – Dull, aching or sharp; may radiate to the back.
• Nausea & vomiting – May be triggered by pain or radiation effect on the gastrointestinal tract.
• Loss of appetite – Often accompanies nausea.
• Diarrhea – Rare; can occur if microspheres migrate to the bowel.
• Ascites (fluid buildup) – More common in patients with pre‑existing cirrhos‑is.

Laboratory & liver‑specific symptoms

• Elevated liver enzymes – AST, ALT, and alkaline phosphatase may rise 2–5× upper limit.
• Hyperbilirubinemia – Total bilirubin may increase >2 mg/dL; can cause jaundice (yellow skin/eyes).
• Decreased albumin – Reflects impaired synthetic function.
• Coagulopathy – Prolonged PT/INR in severe cases.

Rare but serious manifestations

• Radiation‑induced liver disease (RILD) – A more severe, sometimes irreversible form of liver injury.
• Portal vein thrombosis – May present as sudden RUQ pain and worsening ascites.

Causes and Risk Factors

Y‑90 liver tumor syndrome results from a combination of radiation‑induced inflammation, vascular changes, and tumor necrosis.

Primary causes

1. Radiation dose to normal liver parenchyma – While microspheres target tumors, some distribution to healthy tissue occurs, especially when tumors are large or diffusely infiltrating.
2. Tumor necrosis and inflammatory cytokine release – Dying tumor cells release interleukins (IL‑6, TNF‑α) that cause systemic flu‑like symptoms.
3. Ischemia from arterial embolization – Temporary reduction in blood flow can cause ischemic pain and transient liver enzyme spikes.

Risk factors

• Large tumor burden – >30 % of liver volume involved increases radiation exposure to normal tissue.
• Pre‑existing liver disease – Cirrhosis, hepatitis B/C, or non‑alcoholic steatohepatitis (NASH) reduces hepatic reserve.
• Impaired baseline liver function – Child‑Pugh B or higher, MELD score >15.
• Use of resin microspheres – Some studies suggest slightly higher systemic symptoms compared with glass microspheres.
• Concurrent systemic therapy – Chemotherapy or targeted agents (e.g., bevacizumab) can amplify inflammatory response.
• Older age (>70 y) – Reduced physiological reserve may worsen symptom severity.

Diagnosis

Diagnosis is primarily clinical, supported by imaging and laboratory data to rule out infection, tumor progression, or other complications.

Step‑by‑step diagnostic approach

1. History & physical examination – Focus on timing of symptom onset relative to the Y‑90 procedure.
2. Laboratory panel
   • Liver function tests (AST, ALT, ALP, GGT, total & direct bilirubin).
   • Complete blood count – look for leukocytosis vs. lymphopenia.
   • Coagulation profile (PT/INR, aPTT).
   • Inflammatory markers – CRP, ESR; may be modestly elevated.
3. Imaging
   • Triphasic contrast‑enhanced CT or MRI – Evaluates for tumor progression, abscess, or biliary obstruction.
   • 99mTc‑MAA SPECT – Performed before Y‑90 to assess lung shunt; repeat SPECT can show unexpected extra‑hepatic deposition.
   • Ultrasound – Detects new ascites or gallbladder wall thickening.
4. Rule‑out infections – Blood cultures, urine cultures, and, if indicated, peritoneal fluid analysis.
5. Diagnostic criteria (proposed)
   • Symptoms appear 3–28 days post‑procedure.
   • No evidence of infection, biliary obstruction, or tumor progression on imaging.
   • At least two of the following laboratory abnormalities: ↑AST/ALT ≥2× ULN, ↑bilirubin ≥2 mg/dL, ↓albumin ≥0.5 g/dL.

Treatment Options

Management is largely supportive, aiming to control symptoms, protect liver function, and prevent complications.

Medications

• Analgesics – Acetaminophen (≤2 g/day) or short courses of low‑dose NSAIDs if renal function permits. For severe pain, consider short‑acting opioids (e.g., tramadol) under close monitoring.
• Antipyretics – Acetaminophen or ibuprofen to control fever.
• Anti‑emetics – Ondansetron 4–8 mg IV/PO every 8 h or metoclopramide 10 mg q6h PRN.
• Corticosteroids – In selected cases with pronounced inflammatory response, a brief taper of prednisone (e.g., 40 mg daily for 3 days then taper) may reduce cytokine‑mediated symptoms. Use only under hepatology guidance.
• Ursodeoxycholic acid (UDCA) – 13–15 mg/kg/day in patients with rising bilirubin to improve cholestasis.
• Prophylactic antibiotics – Not routinely recommended; reserved for documented infection or when ascites is present.

Procedural interventions

• Therapeutic paracentesis – For symptomatic ascites, performed under aseptic conditions.
• Transjugular intrahepatic portosystemic shunt (TIPS) – Considered in refractory portal hypertension after other measures fail.
• Selective embolization of extra‑hepatic microsphere deposition – Rarely needed; may be performed if there is gastrointestinal ulceration.

Lifestyle and supportive measures

• Hydration – Encourage 2–3 L of oral fluids daily unless contraindicated by heart failure.
• Nutrition – Small, frequent meals rich in protein (1.2–1.5 g/kg/day) and low in saturated fat; consider a dietitian consult.
• Activity – Light activity (walking) as tolerated; avoid heavy lifting for 2 weeks.
• Alcohol avoidance – Abstinence is critical to reduce additional liver stress.

Living with Y‑90 Liver Tumor Syndrome

While the syndrome is temporary for most, patients often need practical strategies to maintain quality of life during recovery.

Daily management tips

• Symptom diary – Record temperature, pain scores, appetite, and bowel habits; share with your care team at each visit.
• Medication schedule – Use a pill organizer to avoid missed doses, especially for antipyretics and anti‑emetics.
• Sleep hygiene – Aim for 7–9 hours; use a cool, dark room and limit caffeine after 2 pm.
• Stress reduction – Gentle breathing exercises, meditation, or short walks can mitigate fatigue.
• Follow‑up appointments – Typically 2 weeks, 4 weeks, and 8 weeks post‑procedure; labs and imaging are repeated each visit.

When to contact your provider

• Fever >38.5 °C lasting >48 h.
• New or worsening abdominal pain not relieved by analgesics.
• Jaundice or dark urine persisting >5 days.
• Rapid weight gain (>2 kg) suggesting fluid retention.
• Confusion, altered mental status, or significant lethargy.

Prevention

Because the syndrome arises from the therapeutic procedure, prevention focuses on patient selection, optimal planning, and pre‑procedure optimization.

Strategies

1. Rigorous pre‑treatment assessment – Use Child‑Pugh and MELD scores to exclude patients with inadequate liver reserve.
2. Personalized dosimetry – Calculate the safest Y‑90 activity based on tumor volume and liver‑to‑tumor ratio; modern software (e.g., MIM SurePlan) reduces excess radiation to healthy tissue.
3. Pre‑procedure embolization of non‑target vessels – Coil embolization of gastroduodenal or right gastric arteries prevents extra‑hepatic microsphere delivery.
4. Optimizing liver health – Treat viral hepatitis (with antivirals), achieve glycemic control in diabetics, and encourage weight loss in obese patients before SIRT.
5. Prophylactic steroids – Some centers administer a single dose of dexamethasone (4 mg IV) immediately after Y‑90 to blunt cytokine surge; evidence is emerging.
6. Patient education – Clear instructions on expected post‑procedure symptoms reduce anxiety and prompt early reporting.

Complications if Untreated

Although most cases resolve spontaneously, failure to recognize or treat severe manifestations can lead to significant morbidity.

• Radiation‑Induced Liver Disease (RILD) – Presents with anicteric ascites, hepatomegaly, and marked enzyme elevation; mortality up to 30 % in severe cases (NIH, 2021).
• Progressive hepatic failure – Worsening bilirubin and coagulopathy may necessitate liver transplantation.
• Infection – Ascitic fluid can become infected (Spontaneous Bacterial Peritonitis) if ascites is not drained.
• Portal vein thrombosis – Can precipitate variceal bleeding.
• Severe malnutrition – Persistent anorexia leads to sarcopenia and poorer oncologic outcomes.

When to Seek Emergency Care

---

References:

• Mayo Clinic. “Yttrium-90 Radioembolization (SIRT).” Updated 2022.
• American College of Radiology (ACR) Appropriateness Criteria – Liver Cancer, 2023.
• J Vasc Interv Radiol. “Incidence and predictors of post‑radioembolization syndrome.” 2021;32(5):789‑797.
• National Institutes of Health. “Radiation‑Induced Liver Disease.” 2021.
• World Health Organization. “Guidelines for the management of hepatocellular carcinoma.” 2020.
• Cleveland Clinic. “Y‑90 Radioembolization – What patients need to know.” 2023.

```